Release time：Sep 22, 2021
On September 19, 2021, the leaders of Shanghai Development and Reform Commission, Shanghai Municipal Commission of Economy and Informatization Technology and Finance Bureau of Shanghai made an on-site investigation to Mabwell. Accompanied by Dr. Liu Datao, co-founder and CEO of the company, the leaders visited Mabwell Innovation and R&D Center and learned about the advantages in scientific and technological innovation development of Mabwell and the progress of key projects on site.
During the symposium, Dr. Liu Datao reported to the leaders the development history of Mabwell, the R&D ability of innovative drugs and the layout of the whole industrial chain, including the capability of source innovation strength and independent innovation strength, the advantages of key products and their development progress, the construction of large-scale commercial production base, the global marketing layout and other development strategies. Then they visited Mabwell Innovation and R&D Center for antibody drugs, and Dr. Liu Datao introduced the innovation and R&D advantages and the advanced platform facilities of the Innovation and R&D Center on site. Mabwell's capability of innovation and R&D strength and pragmatic project construction was fully acknowledged by the leaders.
Director Li Jia, deputy director Zhu Rong of Biomedical Industrial Department, Shanghai Municipal Commission of Economy and Informatization Technology, Zhao Haibo, deputy director of Enterprise Department, Finance Bureau of Shanghai, Cui Kai, official of Department of High-tech Industry, Shanghai Development and Reform Commission, and relevant directors of Mabwell participated in the investigation.
